PureTech Reports New Data Showing Promise for Deupirfenidone for IPF

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease marked by irreversible scarring that steadily impairs breathing, with median survival after diagnosis of between two and five years.

The current FDA-approved therapies, Esbriet (pirfenidone) and Ofev (nintedanib), modestly slow disease progression but often face tolerability challenges, limiting their use. Therefore, patients and providers have hopes riding on research and development that would result in alternatives.

Those hopes got a boost from findings about deupirfenidone, a new IPF drug presented at a European Respiratory Society meeting Sept. 27 to Oct. 1 in Amsterdam.

PureTech , a Boston-based hub-and-spoke biotech company, and Celea Therapeutics, one of PureTech’s subsidiary companies, developed